Exact Sciences' 2024 sales grew 10% to $2.76 billion, exceeding estimates. New cancer tests, including Cologuard Plus, are ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday.Stay Ahead of the ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

That’s why timely screening should be part of your regular health check-upPurdue University’s Center for Healthy Living (CHL), in conjunction with Cologuard® and Exact Sciences, is providing no-cost, ...

They’re non-invasive with none of the dreaded prep. But are recently approved home tests for colon cancer as effective as ...

2 “After having the same discussion year after year with my doctor, he mentioned that there are these Cologuard® box tests for colorectal cancer screening,” Leigh Anne said. “I was so ...

Purdue University’s Center for Healthy Living (CHL), in conjunction with Cologuard® and Exact Sciences, is providing no-cost, noninvasive colon cancer screenings to qualifying benefits-eligible Purdue ...

Exact Sciences Corporation EXAS is focused on further promoting Cologuard as the standard of care. The company prioritizes high-return pipeline opportunities with large patient impacts, which is ...

It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael ...

Unlike a colonoscopy, neither Shield nor Cologuard requires any special preparation, dietary modifications or sedation. “Shield reflects some of the current obstacles of screening,” Dr.